U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363057) titled 'A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors' on Dec. 02, 2025.
Brief Summary: This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Cancer Survivors
Healthy Participant
Elderly
Intervention:
COMBINATION_PRODUCT: GI-102 in combination with GIB-7...